Lifeline Biotechnologies Inc (LLBO)

[voo]

Historical Trial Results

Our iTBra technology was successfully tested with over 200 patients, with a trial originating at The Ohio State University. Cyrcadia Health solution demonstrated an 87% correlation to a verified, clinical diagnosis of breast cancer including with those patients with dense breast tissue. The Ohio State University, along with El Camino Hospital, Mountain View, CA are now undertaking a final 173 patient trial with Cyrcadia.
Core Science
Cyrcadia Health’s technology detects normal circadian cellular baselines, as well as those abnormal patterns associated with the state of cancer. Earliest patient study results indicate that Cyrcadia Health’s accuracy equates to mammography in the identification of cancer, but has improved results with patients that have been diagnosed as having dense tissue.

Current Clinical Trials

Cyrcadia Health intends to show equal to improved results to mammography in the general population with improved results over today’s “gold standards” in the dense tissue population, which entails over 40% of all women. We are also targeting the 70% population of women who have biopsies on non-cancerous tissue due to mammographic referral. Our comfortable, non-compressive and non-irradiative approach will help to populate a global core library on phenotype/genotype, and demographic variables contributing to the state of breast cancer on a worldwide basis.